naa a22 4500 510779190 CHVBK 20180411083241.0 cr unu---uuuuu 180411e20130201xx s 000 0 eng 10.1007/s11892-012-0346-8 doi (NATIONALLICENCE)springer-10.1007/s11892-012-0346-8 Management of Post-Transplant Diabetes [Elektronische Daten] [Ashley Therasse, Amisha Wallia, Mark Molitch] New onset diabetes mellitus after transplant (NODAT) refers to the development of diabetes post-transplant in previously non-diabetic patients and is associated with increased rates of acute transplant rejection, infection, late cardiovascular events, and decreased survival. NODAT is primarily due to the immunosuppressive drug regimen but the standard predisposing risk factors for diabetes also pertain. NODAT is diagnosed by the standard ADA criteria, once prednisone doses are less than 10mg per day and in the absence of acute illness. Sulfonylureas, metformin, DPP-4 inhibitors, GLP-1 agonists, and insulin can be used in treatment, but when there is impaired kidney or hepatic function, special precautions are necessary. In addition, those drugs interacting with P450 enzymes require additional consideration because of possible interaction with immunosuppressive drug metabolism. Springer Science+Business Media New York, 2012 Diabetes nationallicence NODAT nationallicence Transplantation nationallicence Kidney nationallicence Liver nationallicence Lung nationallicence Heart nationallicence Immunosuppression nationallicence Calcineurin nationallicence Cyclosporine nationallicence Tacrolimus nationallicence Sirolimus nationallicence Corticosteroids nationallicence Glucose nationallicence Insulin nationallicence Hyperglycemia nationallicence Metformin nationallicence Glipizide nationallicence Exenatide nationallicence Liraglutide nationallicence Sitagliptin nationallicence Saxagliptin nationallicence Linagliptin nationallicence Therasse Ashley Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 530, 60611, Chicago, IL, USA aut Wallia Amisha Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 530, 60611, Chicago, IL, USA aut Molitch Mark Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 530, 60611, Chicago, IL, USA aut Current Diabetes Reports Current Science Inc. 13/1(2013-02-01), 121-129 1534-4827 13:1<121 2013 13 11892 https://doi.org/10.1007/s11892-012-0346-8 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11892-012-0346-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Therasse Ashley Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 530, 60611, Chicago, IL, USA aut NATIONALLICENCE 700 1- Wallia Amisha Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 530, 60611, Chicago, IL, USA aut NATIONALLICENCE 700 1- Molitch Mark Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, 645 N. Michigan Avenue, Suite 530, 60611, Chicago, IL, USA aut NATIONALLICENCE 773 0- Current Diabetes Reports Current Science Inc 13/1(2013-02-01), 121-129 1534-4827 13:1<121 2013 13 11892 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer